

**Substitute for form 1449A/PTO**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet 1 of 2 Attorney Docket Number ITT0061P

## **U.S. PATENT DOCUMENTS**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number		
3	EP	1162196	A1	Japan Tobacco Inc. (Corresponds to WO01/47883)	12/12/2001
4	WO	02/04425	A2	Boehringer Ingelheim (Canada) Ltd.	01/17/2002
5	EP	1400241	A1	Japan Tobacco Inc. (Corresponds to WO03/000254)	03/24/2004
6	WO	03/010140	A2	Boehringer Ingelheim (Canada) Ltd.	02/06/2003
7	WO	03/010141	A2	Boehringer Ingelheim (Canada) Ltd.	02/06/2003
8	WO	04/065367	A1	Boehringer Ingelheim International GMBH	08/05/2004

Examiner Signature	/Sun Jae Loewe/	Date Considered	02/22/2008
--------------------	-----------------	-----------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>COMPLETE IF KNOWN</b>	
				Application Number	Not Yet Assigned
				Filing Date	April 7, 2006
				First Named Inventor	Avolio, et al.
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	
ITT0061P					

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	9	Von Angerer, E., et al., "2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor inhibiting activity", Journal of Medicinal Chemistry, Vol. 30, No. 1, pp. 131-136 (1987)
	10	Traxler, P. M., et al., "4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase", Journal of Medicinal Chemistry, Vol. 39, No. 12, pp. 2285-2292 (1996)
	11	Chi, S. M., et al., "Palladium-catalyzed functionalization of 5- and 7-azaindoles", Tetrahedron Letters, Vol. 41, No. 6, pp. 919-922 (2000)
	12	Zhang, H. C., et al., "Efficient synthesis of 3-substituted 2-arylindoles via Suzuki coupling reactions on the solid phase", Tetrahedron Letters, Vol. 42, No. 29, pp. 4751-4754 (2001)
	13	Engler, T. A., et al., "Lewis Acid-Controlled Regioselectivity in Reactions of Styrenyl Systems with Benzoquinone Monoimides: New Regioselective Syntheses of Substituted 2-Aryl-2,3-dihydrobenzofurans, 2-Aryl-2,3-dihydroindoles, and 2-Arylindoles", J. Org. Chem., Vol. 61, No. 26, pp. 9297-9308 (1996)
	14	Derwent Abstract No. 2003-221366/21, "Antihepatitis C agents comprise new and known fused cyclic compounds", Japan Tobacco Inc., Abstract of WO03/000254
	15	Derwent Abstract No. 2001-514316/56, "New bicyclic compounds are hepatitis C polymerase inhibitors for treating and preventing hepatitis C", Japan Tobacco Inc., Abstract of WO01/47883
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./		

Examiner Signature	/Sun Jae Loewe/	Date Considered	02/22/2008
--------------------	-----------------	-----------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005